Biomedical Informatics Research Laboratory, Department of Biology, Lahore University of Management Sciences, Lahore, Pakistan.
Virology Laboratory, Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
Med Res Rev. 2019 May;39(3):1091-1136. doi: 10.1002/med.21554. Epub 2018 Dec 2.
Hepatitis C compromises the quality of life of more than 350 million individuals worldwide. Over the last decade, therapeutic regimens for treating hepatitis C virus (HCV) infections have undergone rapid advancements. Initially, structure-based drug design was used to develop molecules that inhibit viral enzymes. Subsequently, establishment of cell-based replicon systems enabled investigations into various stages of HCV life cycle including its entry, replication, translation, and assembly, as well as role of host proteins. Collectively, these approaches have facilitated identification of important molecules that are deemed essential for HCV life cycle. The expanded set of putative virus and host-encoded targets has brought us one step closer to developing robust strategies for efficacious, pangenotypic, and well-tolerated medicines against HCV. Herein, we provide an overview of the development of various classes of virus and host-directed therapies that are currently in use along with others that are undergoing clinical evaluation.
丙型肝炎影响着全球超过 3.5 亿人的生活质量。在过去的十年中，治疗丙型肝炎病毒（HCV）感染的治疗方案取得了快速进展。最初，基于结构的药物设计被用于开发抑制病毒酶的分子。随后，建立基于细胞的复制子系统使人们能够研究 HCV 生命周期的各个阶段，包括其进入、复制、翻译和组装，以及宿主蛋白的作用。总的来说，这些方法促进了对被认为对 HCV 生命周期至关重要的重要分子的鉴定。扩大的潜在病毒和宿主编码靶点集使我们离开发针对 HCV 的有效、全基因型和耐受性良好的药物的稳健策略又近了一步。本文概述了目前正在使用的以及正在临床评估的各种类型的病毒和宿主定向治疗的发展情况。
